Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:24 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy
NCT01806649 · Prince of Songkla University · PHASE2 · terminated · last registry update 2021-10-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor terminated to continue any clinical trials with study drug” | – | Registry record, Prince of Songkla University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PIK3R1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-08-22Also stopped (terminated): Vanderbilt-Ingram Cancer Center, Enzalutamide + Taselisib (NCT02457910)
- 2022-08-16Phase 3 first posted: Celcuity Inc, Gedatolisib + Palbociclib (NCT05501886)
- 2022-07-28Also stopped (withdrawn): Rutgers, The State University of New Jersey, BKM120 + Nabpaclitaxel (NCT02117817)
- 2022-07-12Also stopped (terminated): Hoffmann-La Roche, Taselisib + Placebo (NCT02340221)
- 2022-05-18Also stopped (terminated): SignalRX Pharmaceuticals, Inc., SF1126 + Nivolumab (NCT03059147)
- 2022-02-01Results posted on the registry: US Oncology Research, BKM120 + capecitabine (NCT02000882)
- 2021-10-07Results posted on the registry: Pfizer, PF-05212384 (gedatolisib) + Docetaxel (NCT01920061)
- 2021-06-23Results posted on the registry: Restorbio Inc., Dactolisib (NCT04668352)
- 2021-06-21Results posted on the registry: Memorial Sloan Kettering Cancer Center, Buparlisib (NCT01551030)
- 2021-02-10Also stopped (terminated): Restorbio Inc., RTB101 + Placebo (NCT04409327)
- 2021-01-13Results posted on the registry: Won Kim, BKM120 (NCT01695473)
- 2021-01-13Also stopped (terminated): Won Kim, BKM120 (NCT01695473)
- 2020-12-19Also stopped (terminated): Novartis Pharmaceuticals, INC424 + BKM120 (NCT01730248)
- 2020-12-16Phase 3 first posted: Restorbio Inc., Dactolisib (NCT04668352)
- 2020-12-08Also stopped (terminated): Novartis Pharmaceuticals, BEZ235 + Paclitaxel (NCT01495247)
- 2020-10-28Results posted on the registry: SOLTI Breast Cancer Research Group, BKM120 (NCT01629615)
- 2020-10-27Results posted on the registry: University of Chicago, PI3K inhibitor BKM120 + cetuximab (NCT01816984)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision